Enterprise Value

619.2M

Cash

180.9M

Avg Qtr Burn

-34.6M

Short % of Float

4.06%

Insider Ownership

18.18%

Institutional Own.

75.23%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WVE-N531 Details
Duchenne muscular dystrophy

Phase 2

Data readout

WVE-003 Details
Huntington's disease

Phase 1/2

Data readout

WVE-006 Details
Alpha-1 Antitrypsin Deficiency

Phase 1

Data readout

Phase 1

Initiation

WVE-120101 (SNP1) Details
Huntington's disease

Failed

Discontinued

WVE-120102 (SNP2) Details
Huntington's disease

Failed

Discontinued

WVE-004 Details
Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations

Failed

Discontinued